ACT announces clinical trials for myopia

Advance Cell Technology (ACT) just announced that it has received approval from the FDA to commence Phase I/II stem cell clinical trials on patients with severe myopia (nearsightedness). The main purpose of the trials is to evaluate the safety of ACT's product, containing retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells.The trials will be led by Steven Schwartz, professor of Ophthalmology at the David Geffen School of Medicine at the University of California, Los […]